NOVATO, Calif., Oct. 25, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq:RPTP), announced today that the Company concluded a pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) related to its investigational drug candidate, RP103 (delayed-release formulation of cysteamine bitartrate), for the treatment of nephropathic cystinosis. The purpose of the meeting was to discuss the proposed NDA and to confirm the clinical, non-clinical and manufacturing requirements for the Company’s NDA submission, which the Company intends to file in the first quarter of 2012, as previously announced.
